Cancers (Jun 2021)
Dissection of <i>PIK3CA</i> Aberration for Cervical Adenocarcinoma Outcomes
- Tony K. H. Chung,
- Graeme Doran,
- Tak-Hong Cheung,
- So-Fan Yim,
- Mei-Yung Yu,
- Michael J. Worley,
- Kevin M. Elias,
- Aaron R. Thorner,
- Chandra Sekhar Pedamallu,
- Akinyemi I. Ojesina,
- Kei-Man Lau,
- Matthew D. Ducar,
- Raymond R. Y. Wong,
- Vivian W. Wang,
- Anwesha Nag,
- Bruce M. Wollison,
- Audrey Dalgarno,
- Jacqueline H. S. Lee,
- Suet-Ying Yeung,
- Lo Wong,
- Neil S. Horowitz,
- Michelle R. Davis,
- Shuk-On A. Leung,
- Yi Mu,
- Samuel C. Mok,
- Paul K. S. Chan,
- Michael S. Lawrence,
- Christopher P. Crum,
- Rossa W. K. Chiu,
- Ross S. Berkowitz,
- Yick-Fu Wong
Affiliations
- Tony K. H. Chung
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- Graeme Doran
- Firefly Bioworks, Inc., Cambridge, MA 02139, USA
- Tak-Hong Cheung
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- So-Fan Yim
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- Mei-Yung Yu
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- Michael J. Worley
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA
- Kevin M. Elias
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA
- Aaron R. Thorner
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA
- Chandra Sekhar Pedamallu
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA
- Akinyemi I. Ojesina
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
- Kei-Man Lau
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- Matthew D. Ducar
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA
- Raymond R. Y. Wong
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- Vivian W. Wang
- Mayo Clinic, Rochester, MN 55902, USA
- Anwesha Nag
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA
- Bruce M. Wollison
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA
- Audrey Dalgarno
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA
- Jacqueline H. S. Lee
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- Suet-Ying Yeung
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- Lo Wong
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- Neil S. Horowitz
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA
- Michelle R. Davis
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA
- Shuk-On A. Leung
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA
- Yi Mu
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA
- Samuel C. Mok
- MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA
- Paul K. S. Chan
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- Michael S. Lawrence
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
- Christopher P. Crum
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA
- Rossa W. K. Chiu
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- Ross S. Berkowitz
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA
- Yick-Fu Wong
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
- DOI
- https://doi.org/10.3390/cancers13133218
- Journal volume & issue
-
Vol. 13,
no. 13
p. 3218
Abstract
Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient’s circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women’s cancer.
Keywords
